A Phase 1 interventional study of Depemokimab in Asthma, sponsored by GlaxoSmithKline. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.
Among the 10 studies testing depemokimab in Asthma, this one is the 10th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 1, and was the 5th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 6–11
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 12+
GlaxoSmithKline · Sites in United States, Belgium, Canada and 9 more countries
Ages 18+
By country, each count listing its studies:
depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2021.
This study's enrollment of 20 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 273 across the 10 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 200th largest by enrollment of the 238 interventional ones that give a count, is one of 7 that started in 2021, is one of 62 in phase 1, and was the 241st registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing depemokimab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing depemokimab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This single dose pharmacokinetic (PK) study aims to investigate the PK, safety, tolerability and immunogenicity of two dose levels of GSK3511294 administered subcutaneously in Chinese healthy participants
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.
Biological: Depemokimab
Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Biological: Depemokimab
Depemokimab was administered.
Also known as: GSK3511294
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero (Pre-Dose) Extrapolated to Infinite Time (AUC[0-Infinity]) of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Infinity). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
Time frame: Day 1 (Pre-dose, 2h, and 8h Post-dose), Day 2, Day 3, Day 5, Day 8, Day 15, Day 29, Day 57, Day 85, Day 127, Day 169, and Day 183
AUC From Time 0 (Pre-Dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC[0-T]) of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for AUC(0-T). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
Time frame: Day 1 (Pre-dose, 2h, and 8h Post-dose), Day 2, Day 3, Day 5, Day 8, Day 15, Day 29, Day 57, Day 85, Day 127, Day 169, and Day 183
AUC From Time 0 (Pre-dose) to Week 4 (AUC[0-Week 4]) of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 4). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 4 post-dose correlates to Day 1 plus 28 days, that is, Day 29.
Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, and 29
AUC From Time 0 (Pre-dose) To Week 12 (AUC[0-Week 12]) Of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 12). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, that is, Day 85.
Time frame: Pre-dose (Day 1); 2 h, 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, and 85
AUC From Time 0 (Pre-dose) To Week 26 [AUC(0-Week 26)] of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 26). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Percentage Of AUC(0-Infinity) Obtained by Extrapolation (%AUCex) of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for percentage of AUC(0-Infinity) obtained by extrapolation. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Maximum Observed Plasma Concentration (Cmax) of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for Cmax. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Time of Occurrence of Cmax (Tmax) Of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for Tmax. Pharmacokinetic parameters were calculated by standard non compartmental analysis. Tmax was determined directly from the plasma concentration-time data. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Time To Last Quantifiable Concentration (Tlast) of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for Tlast. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
Time frame: Pre-dose (day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Apparent Clearance (CL/F) of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for Apparent Clearance. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Apparent Volume of Distribution (Vz/F) of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for apparent volume of distribution. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Terminal Elimination Rate Constant (Lambda Z) of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for Terminal elimination rate constant. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Terminal Phase Half-Life (T1/2) of Depemokimab
Blood samples were collected from participants at indicated time points and analyzed for Terminal phase half-life. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Number of Participants With Adverse Events (AE) And Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or is considered or defined as an important medical event.
Time frame: From the start of the study intervention (Day 1) up to Day 211 (End of follow-up)
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes
Blood samples were collected for the assessment of hematology parameters including (WBC) count with differential that is, Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26
Change From Baseline in Hematology Parameter: Hemoglobin
Blood samples were collected for the assessment of change from baseline in hematology parameters including Hemoglobin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26
Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected for the assessment of change from baseline in hematology parameters including Hematocrit. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)
Blood samples were collected for the assessment of change from baseline in hematology parameters including mean corpuscular volume. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
Blood samples were collected for the assessment of change from baseline in hematology parameters including mean Corpuscular Hemoglobin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26
Change From Baseline in Hematology Parameter: Reticulocytes
Blood samples were collected for the assessment of change from baseline in hematology parameters including Reticulocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26
Change From Baseline In Hematology Parameter: Erythrocytes
Change from baseline in hematology parameter including Erythrocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea
Blood samples was collected for the assessment of clinical chemistry parameters including Sodium, potassium, calcium, glucose, and urea. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Pre-dose on Day -1), Week 1, 4, 8, 12, 24 and Week 26
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine
Blood samples was collected for the assessment of clinical chemistry parameters including direct bilirubin, bilirubin, and creatinine\[MB10.1\]. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT)
Blood samples was collected for the assessment of clinical chemistry parameters including AST, ALT, ALP, and GGT. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein
Blood samples was collected for the assessment of clinical chemistry parameters including Albumin. and Total Protein. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26
Absolute Values of Complement C3 And C4 at Each Timepoint
Blood samples were collected at indicated timepoints for analysis for complement (C3 and C4). Baseline was defined as latest pre-dose assessment with a non-missing value.
Time frame: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26
Ratio to Baseline at Each Timepoint of Complement C3 And C4
Blood samples were collected at indicated timepoints for analysis for complement (C3 and C4). Baseline was defined as latest pre-dose assessment with a non-missing value.
Time frame: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26
Change From Baseline in Systolic and Diastolic Blood Pressure
Systolic blood pressure (sBP) is a measure of blood pressure while the heart is beating. Diastolic blood pressure (dBP) is a measure of blood pressure while the heart is relaxed. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Day 1 (2 hours), Day 1 (8 hours), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26
Change From Baseline in Body Temperature
Body temperature was measured in participants in resting state. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Day 1 (2 hours), Day 1 (8 hours), Day 2, 3, 5, Week 1, 2, 4, 8, 12, 18, 24 and 26
Change From Baseline in Pulse Rate
The vital signs followed in this analysis was pulse rate, expressed as beats per minute (bpm). Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Day 1 (2 hour), Day 1 (8 hour), Day 2, 3, 5, Week 1, 4, 8, 12, 18, 24 and Week 26
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate
12-lead ECG were performed in a supine position using an automated ECG machine that calculated the heart rate and measured PR interval, QRS duration, QT interval and corrected QT using Fridericia's Formula (QTc\[MB13.1\]F) intervals. ECG measurements were performed in triplicate. When multiple ECGs were performed at the same planned timepoint, the aggregate \[MB14.1\]value of each parameter was used. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day -1), Day 1 (2 hour), Day 1 (8 hour), Day 2, 3, 5, Week 1, 4, 8, 12, 18, 24 and Week 26
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Depemokimab
Serum samples were collected to determine the presence of anti-depemokimab binding antibodies using a validated bioanalytical method. Data is reported by visit. The results were categorized as negative and positive. A participant is considered positive if they have at least one positive post-Baseline ADA result. Number of participants with positive ADAs against depemokimab was reported in this outcome measure.
Time frame: Day 1 (Pre-dose), Week 4, Week 12, and Week 26
Titres of Binding ADA's to Depemokimab
Serum samples were collected to determine the presence of anti-depemokimab binding antibodies using a validated bioanalytical method. Data is reported by visit. Titer was only measured when a positive result was found.
Time frame: Up to Week 26
| Milestone | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 9 |
| Not completed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Infinity). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
| day*micrograms per millilitres | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero (Pre-Dose) Extrapolated to Infinite Time (AUC[0-Infinity]) of Depemokimab | 1685.946 (1540.9579 to 1844.5771) | 5224.107 (4713.2900 to 5790.2848) |
Blood samples were collected from participants at indicated time points and analyzed for AUC(0-T). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
| day*micrograms per millilitres | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| AUC From Time 0 (Pre-Dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC[0-T]) of Depemokimab | 1472.963 (1346.2052 to 1611.6562) | 4604.879 (4133.2379 to 5130.3394) |
Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 4). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 4 post-dose correlates to Day 1 plus 28 days, that is, Day 29.
| day*micrograms per millilitres | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| AUC From Time 0 (Pre-dose) to Week 4 (AUC[0-Week 4]) of Depemokimab | 414.467 (367.9103 to 466.9157) | 1357.843 (1207.8494 to 1526.4621) |
Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 12). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, that is, Day 85.
| day*micrograms per millilitres | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| AUC From Time 0 (Pre-dose) To Week 12 (AUC[0-Week 12]) Of Depemokimab | 1027.083 (933.7879 to 1129.6990) | 3255.132 (2902.9404 to 3650.0522) |
Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 26). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
| day*micrograms per millilitres | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| AUC From Time 0 (Pre-dose) To Week 26 [AUC(0-Week 26)] of Depemokimab | 1472.912 (1346.2052 to 1611.5454) | 4605.772 (4134.0654 to 5131.3018) |
Blood samples were collected from participants at indicated time points and analyzed for percentage of AUC(0-Infinity) obtained by extrapolation. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
| Percentage of AUCex | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Percentage Of AUC(0-Infinity) Obtained by Extrapolation (%AUCex) of Depemokimab | 12.381 (10.7508 to 14.2591) | 11.611 (9.9214 to 13.5888) |
Blood samples were collected from participants at indicated time points and analyzed for Cmax. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
| micrograms per milliliters (mcg/mL) | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Depemokimab | 16.82 (14.782 to 19.144) | 55.04 (48.183 to 62.867) |
Blood samples were collected from participants at indicated time points and analyzed for Tmax. Pharmacokinetic parameters were calculated by standard non compartmental analysis. Tmax was determined directly from the plasma concentration-time data. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
| Days | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Time of Occurrence of Cmax (Tmax) Of Depemokimab | 13.960 (3.98 to 27.95) | 13.980 (4.00 to 27.98) |
Blood samples were collected from participants at indicated time points and analyzed for Tlast. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
| Days | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Time To Last Quantifiable Concentration (Tlast) of Depemokimab | 181.980 (181.97 to 182.19) | 181.980 (180.96 to 182.06) |
Blood samples were collected from participants at indicated time points and analyzed for Apparent Clearance. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
| Liters per day | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Apparent Clearance (CL/F) of Depemokimab | 0.0593 (0.0542 to 0.0649) | 0.0574 (0.0518 to 0.0636) |
Blood samples were collected from participants at indicated time points and analyzed for apparent volume of distribution. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
| Litres | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Depemokimab | 5.033 (4.5599 to 5.5554) | 4.827 (4.2489 to 5.4830) |
Blood samples were collected from participants at indicated time points and analyzed for Terminal elimination rate constant. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
| Per Day | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Terminal Elimination Rate Constant (Lambda Z) of Depemokimab | 0.0118 (0.0111 to 0.0125) | 0.0119 (0.0112 to 0.0127) |
Blood samples were collected from participants at indicated time points and analyzed for Terminal phase half-life. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.
| Days | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Terminal Phase Half-Life (T1/2) of Depemokimab | 58.827 (55.5367 to 62.3132) | 58.246 (54.7008 to 62.0215) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or is considered or defined as an important medical event.
| Participants | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Adverse Events | 10 | 10 |
| Serious Adverse Events | 0 | 0 |
Blood samples were collected for the assessment of hematology parameters including (WBC) count with differential that is, Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| 10^9 cells/L | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Basophils, Day 2 | -0.000 ± 0.0125 | -0.007 ± 0.0082 |
| Basophils, Day 3 | -0.006 ± 0.0126 | -0.002 ± 0.0123 |
| Basophils, Day 5 | -0.005 ± 0.0127 | -0.002 ± 0.0132 |
| Basophils, Week 1 | -0.007 ± 0.0082 | -0.009 ± 0.0074 |
| Basophils, Week 2 | -0.006 ± 0.0107 | -0.009 ± 0.0099 |
| Basophils, Week 4 | -0.010 ± 0.0156 | -0.009 ± 0.0129 |
| Basophils, Week 8 | -0.001 ± 0.0120 | -0.011 ± 0.0129 |
| Basophils, Week 12 | -0.010 ± 0.0105 | -0.014 ± 0.0133 |
| Basophils, Week 18 | -0.009 ± 0.0099 | -0.009 ± 0.0105 |
| Basophils, Week 24 | -0.005 ± 0.0135 | -0.016 ± 0.0174 |
| Basophils, Week 26 | -0.004 ± 0.0135 | -0.007 ± 0.0100 |
| Eosinophils, Day 2 | -0.090 ± 0.0720 | -0.046 ± 0.0401 |
| Eosinophils, Day 3 | -0.101 ± 0.0824 | -0.049 ± 0.0463 |
| Eosinophils, Day 5 | -0.114 ± 0.0875 | -0.059 ± 0.0404 |
| Eosinophils, Week 1 | -0.117 ± 0.0858 | -0.060 ± 0.0429 |
| Eosinophils, Week 2 | -0.122 ± 0.0889 | -0.055 ± 0.0414 |
| Eosinophils, Week 4 | -0.128 ± 0.0986 | -0.063 ± 0.0499 |
| Eosinophils, Week 8 | -0.129 ± 0.1092 | -0.068 ± 0.0432 |
| Eosinophils, Week 12 | -0.132 ± 0.1017 | -0.068 ± 0.0435 |
| Eosinophils, Week 18 | -0.123 ± 0.0943 | -0.064 ± 0.0522 |
| Eosinophils, Week 24 | -0.126 ± 0.0982 | -0.077 ± 0.0480 |
| Eosinophils, Week 26 | -0.122 ± 0.0919 | -0.069 ± 0.0506 |
| Lymphocytes, Day 2 | -0.23 ± 0.337 | -0.11 ± 0.088 |
| Lymphocytes, Day 3 | -0.32 ± 0.385 | -0.16 ± 0.276 |
| Lymphocytes, Day 5 | -0.14 ± 0.337 | -0.18 ± 0.204 |
| Lymphocytes, Week 1 | -0.20 ± 0.327 | -0.23 ± 0.177 |
| Lymphocytes, Week 2 | -0.03 ± 0.440 | 0.01 ± 0.191 |
| Lymphocytes, Week 4 | 0.12 ± 0.505 | -0.09 ± 0.260 |
| Lymphocytes, Week 8 | 0.16 ± 0.320 | 0.03 ± 0.353 |
| Lymphocytes, Week 12 | -0.21 ± 0.331 | -0.04 ± 0.381 |
| Lymphocytes, Week 18 | -0.11 ± 0.384 | -0.12 ± 0.291 |
| Lymphocytes, Week 24 | -0.20 ± 0.422 | -0.20 ± 0.418 |
| Lymphocytes, Week 26 | -0.21 ± 0.477 | -0.18 ± 0.427 |
| Monocytes, Day 2 | -0.05 ± 0.085 | 0.01 ± 0.057 |
| Monocytes, Day 3 | -0.06 ± 0.084 | 0.04 ± 0.052 |
| Monocytes, Day 5 | 0.01 ± 0.088 | 0.05 ± 0.053 |
| Monocytes, Week 1 | -0.05 ± 0.097 | 0.04 ± 0.117 |
| Monocytes, Week 2 | -0.04 ± 0.126 | 0.01 ± 0.074 |
| Monocytes, Week 4 | 0.00 ± 0.115 | 0.01 ± 0.057 |
| Monocytes, Week 8 | 0.04 ± 0.052 | 0.07 ± 0.125 |
| Monocytes, Week 12 | -0.06 ± 0.107 | 0.09 ± 0.060 |
| Monocytes, Week 18 | -0.02 ± 0.092 | 0.08 ± 0.109 |
| Monocytes, Week 24 | -0.02 ± 0.079 | 0.04 ± 0.053 |
| Monocytes, Week 26 | -0.03 ± 0.116 | 0.07 ± 0.100 |
| Neutrophils, Day 2 | 0.12 ± 1.497 | 0.05 ± 0.693 |
| Neutrophils, Day 3 | -0.45 ± 0.992 | 0.08 ± 0.960 |
| Neutrophils, Day 5 | -0.15 ± 0.941 | 0.08 ± 1.090 |
| Neutrophils, Week 1 | -0.52 ± 1.052 | -0.21 ± 1.179 |
| Neutrophils, Week 2 | 0.19 ± 1.819 | -0.12 ± 0.878 |
| Neutrophils, Week 4 | -0.42 ± 1.096 | -0.01 ± 0.679 |
| Neutrophils, Week 8 | -0.16 ± 1.178 | -0.09 ± 1.175 |
| Neutrophils, Week 12 | -0.48 ± 1.212 | 0.19 ± 0.483 |
| Neutrophils, Week 18 | -0.39 ± 1.112 | 0.79 ± 0.770 |
| Neutrophils, Week 24 | -0.06 ± 0.999 | 0.33 ± 0.819 |
| Neutrophils, Week 26 | -0.13 ± 1.591 | 0.77 ± 1.052 |
| Platelets, Day 2 | -10.8 ± 12.56 | 5.7 ± 12.81 |
| Platelets, Day 3 | -1.9 ± 14.16 | -0.3 ± 13.75 |
| Platelets, Day 5 | -6.1 ± 10.18 | 1.7 ± 15.90 |
| Platelets, Week 1 | -21.8 ± 14.17 | -5.5 ± 11.71 |
| Platelets, Week 2 | -9.4 ± 19.97 | 4.5 ± 15.50 |
| Platelets, Week 4 | -10.4 ± 15.77 | 7.5 ± 19.55 |
| Platelets, Week 8 | -13.6 ± 23.77 | 3.4 ± 23.24 |
| Platelets, Week 12 | -15.6 ± 23.68 | 4.3 ± 47.56 |
| Platelets, Week 18 | -11.2 ± 20.43 | -1.7 ± 29.48 |
| Platelets, Week 24 | -22.7 ± 19.45 | 22.6 ± 18.77 |
| Platelets, Week 26 | -18.9 ± 22.26 | -2.7 ± 25.31 |
| Leukocytes, Day 2 | -0.240 ± 1.5414 | -0.070 ± 0.7424 |
| Leukocytes, Day 3 | -0.900 ± 0.9752 | -0.100 ± 0.9404 |
| Leukocytes, Day 5 | -0.390 ± 0.8465 | -0.080 ± 1.1203 |
| Leukocytes, Week 1 | -0.880 ± 1.2506 | -0.480 ± 1.1203 |
| Leukocytes, Week 2 | -0.020 ± 1.7061 | -0.140 ± 1.0035 |
| Leukocytes, Week 4 | -0.400 ± 1.4314 | -0.180 ± 0.7899 |
| Leukocytes, Week 8 | -0.090 ± 1.0546 | -0.080 ± 1.4382 |
| Leukocytes, Week 12 | -0.870 ± 1.3073 | 0.111 ± 0.5883 |
| Leukocytes, Week 18 | -0.640 ± 1.1197 | 0.667 ± 0.7778 |
| Leukocytes, Week 24 | -0.400 ± 1.1025 | 0.034 ± 0.8914 |
| Leukocytes, Week 26 | -0.470 ± 1.4476 | 0.048 ± 1.6991 |
Blood samples were collected for the assessment of change from baseline in hematology parameters including Hemoglobin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Gram per Liter | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Day 2 | -3.5 ± 7.68 | -2.1 ± 2.81 |
| Day 3 | -1.0 ± 6.25 | -5.2 ± 4.85 |
| Day 5 | -3.6 ± 10.86 | -6.2 ± 5.63 |
| Week 1 | -6.4 ± 10.94 | -7.0 ± 5.64 |
| Week 2 | -2.5 ± 7.88 | -7.5 ± 6.35 |
| Week 4 | -2.5 ± 7.88 | -5.8 ± 7.19 |
| Week 8 | -0.7 ± 9.27 | -8.9 ± 4.79 |
| Week 12 | -2.2 ± 8.30 | -8.9 ± 8.77 |
| Week 18 | -2.3 ± 8.83 | -4.0 ± 6.12 |
| Week 24 | -4.3 ± 8.59 | -5.4 ± 5.66 |
| Week 26 | -4.3 ± 6.63 | -2.6 ± 7.49 |
Blood samples were collected for the assessment of change from baseline in hematology parameters including Hematocrit. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Liter/liter | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Day 2 | -0.0112 ± 0.0148 | -0.0191 ± 0.0105 |
| Day 3 | -0.0077 ± 0.0195 | -0.0231 ± 0.0197 |
| Day 5 | -0.0136 ± 0.0311 | -0.0170 ± 0.0180 |
| Week 1 | -0.0189 ± 0.0327 | -0.0194 ± 0.0170 |
| Week 2 | -0.0075 ± 0.0202 | -0.0210 ± 0.0173 |
| Week 4 | -0.0092 ± 0.0202 | -0.0174 ± 0.0181 |
| Week 8 | 0.0029 ± 0.0248 | -0.0210 ± 0.0163 |
| Week 12 | -0.0032 ± 0.0232 | -0.0241 ± 0.0221 |
| Week 18 | -0.0093 ± 0.0234 | -0.0084 ± 0.0161 |
| Week 24 | 0.0003 ± 0.0252 | -0.0149 ± 0.0099 |
| Week 26 | -0.0021 ± 0.0164 | -0.0158 ± 0.0169 |
Blood samples were collected for the assessment of change from baseline in hematology parameters including mean corpuscular volume. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Femtoliters | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Day 2 | -0.75 ± 0.746 | -0.23 ± 0.403 |
| Day 3 | 1.41 ± 1.457 | 0.60 ± 0.400 |
| Day 5 | -0.22 ± 0.773 | 0.26 ± 0.493 |
| Week 1 | -0.46 ± 0.769 | 0.09 ± 0.318 |
| Week 2 | -0.07 ± 0.607 | 0.17 ± 0.760 |
| Week 4 | 0.07 ± 1.002 | 0.53 ± 0.898 |
| Week 8 | 0.33 ± 1.124 | 0.77 ± 1.087 |
| Week 12 | -0.27 ± 1.427 | -0.10 ± 2.062 |
| Week 18 | -0.13 ± 1.425 | 0.27 ± 1.885 |
| Week 24 | 0.50 ± 0.627 | 0.56 ± 1.544 |
| Week 26 | 0.37 ± 0.974 | -0.96 ± 1.726 |
Blood samples were collected for the assessment of change from baseline in hematology parameters including mean Corpuscular Hemoglobin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Picograms (pg) | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Day 2 | -0.01 ± 0.166 | 0.81 ± 0.360 |
| Day 3 | 0.86 ± 0.438 | 0.72 ± 0.592 |
| Day 5 | 0.20 ± 0.462 | -0.04 ± 0.267 |
| Week 1 | -0.13 ± 0.206 | -0.04 ± 0.313 |
| Week 2 | -0.16 ± 0.255 | 0.04 ± 0.558 |
| Week 4 | 0.13 ± 0.432 | 0.18 ± 0.416 |
| Week 8 | -0.18 ± 0.266 | -0.09 ± 0.702 |
| Week 12 | -0.33 ± 0.374 | -0.21 ± 0.395 |
| Week 18 | 0.17 ± 0.241 | -0.11 ± 0.504 |
| Week 24 | -0.69 ± 0.273 | 0.07 ± 0.579 |
| Week 26 | -0.55 ± 0.350 | 0.24 ± 0.754 |
Blood samples were collected for the assessment of change from baseline in hematology parameters including Reticulocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Percentage | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Day 2 | -0.052 ± 0.1471 | 0.085 ± 0.0669 |
| Day 3 | 0.601 ± 0.6413 | 0.162 ± 0.0933 |
| Day 5 | 0.083 ± 0.2090 | 0.046 ± 0.1254 |
| Week 1 | 0.004 ± 0.1593 | 0.071 ± 0.1091 |
| Week 2 | -0.047 ± 0.1636 | 0.118 ± 0.1686 |
| Week 4 | 0.123 ± 0.4205 | 0.134 ± 0.1686 |
| Week 8 | 0.107 ± 0.3578 | 0.682 ± 0.4978 |
| Week 12 | 0.137 ± 0.1762 | 0.656 ± 0.2779 |
| Week 18 | 0.037 ± 0.2155 | 0.312 ± 0.1923 |
| Week 24 | 0.126 ± 0.1675 | 0.624 ± 0.3206 |
| Week 26 | 0.099 ± 0.1200 | 0.318 ± 0.2828 |
Change from baseline in hematology parameter including Erythrocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| 10^12 cells per liter | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Day 2 | -0.083 ± 0.1904 | -0.197 ± 0.1225 |
| Day 3 | -0.160 ± 0.2322 | -0.289 ± 0.2102 |
| Day 5 | -0.138 ± 0.3643 | -0.205 ± 0.2059 |
| Week 1 | -0.182 ± 0.3466 | -0.221 ± 0.1875 |
| Week 2 | -0.080 ± 0.2262 | -0.242 ± 0.2060 |
| Week 4 | -0.104 ± 0.1979 | -0.225 ± 0.2154 |
| Week 8 | 0.011 ± 0.2986 | -0.271 ± 0.1777 |
| Week 12 | -0.019 ± 0.2729 | -0.258 ± 0.2909 |
| Week 18 | -0.097 ± 0.2589 | -0.107 ± 0.2389 |
| Week 24 | -0.026 ± 0.2611 | -0.189 ± 0.1619 |
| Week 26 | -0.043 ± 0.1945 | -0.123 ± 0.2421 |
Blood samples was collected for the assessment of clinical chemistry parameters including Sodium, potassium, calcium, glucose, and urea. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Millimoles per liter | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Sodium, Week 1 | 1.1 ± 1.10 | 0.9 ± 1.73 |
| Sodium, Week 4 | -0.3 ± 1.57 | 0.1 ± 1.91 |
| Sodium, Week 8 | 0.3 ± 1.06 | 0.9 ± 2.23 |
| Sodium, Week 12 | -1.1 ± 1.79 | -0.1 ± 2.09 |
| Sodium, Week 24 | -1.7 ± 2.50 | 0.7 ± 2.29 |
| Sodium, Week 26 | -0.9 ± 1.60 | 0.1 ± 1.83 |
| Potassium, Week 1 | 0.045 ± 0.1932 | -0.106 ± 0.1246 |
| Potassium, Week 4 | -0.031 ± 0.2265 | -0.189 ± 0.2365 |
| Potassium, Week 8 | -0.028 ± 0.3262 | -0.242 ± 0.1728 |
| Potassium, Week 12 | -0.042 ± 0.2665 | -0.427 ± 0.2293 |
| Potassium, Week 24 | -0.131 ± 0.2347 | -0.098 ± 0.1161 |
| Potassium, Week 26 | -0.106 ± 0.2360 | -0.252 ± 0.1716 |
| Calcium, Week 1 | 0.052 ± 0.1105 | -0.037 ± 0.0295 |
| Calcium, Week 4 | 0.010 ± 0.1159 | -0.002 ± 0.0432 |
| Calcium, Week 8 | 0.065 ± 0.1084 | -0.018 ± 0.1054 |
| Calcium, Week 12 | 0.039 ± 0.1034 | -0.017 ± 0.0901 |
| Calcium, Week 24 | 0.073 ± 0.1335 | 0.021 ± 0.0326 |
| Calcium, Week 26 | 0.018 ± 0.1036 | -0.111 ± 0.0824 |
| Urea, Week 1 | 0.447 ± 1.1678 | 0.084 ± 0.8962 |
| Urea, Week 4 | 0.083 ± 0.6965 | 0.679 ± 0.9138 |
| Urea, Week 8 | 0.251 ± 0.8523 | 0.164 ± 1.0094 |
| Urea, Week 12 | 0.069 ± 0.6141 | 0.102 ± 0.6358 |
| Urea, Week 24 | 0.215 ± 0.7788 | 0.318 ± 0.5073 |
| Urea, Week 26 | 0.179 ± 0.9985 | 0.067 ± 0.9667 |
| Glucose, Week 1 | 0.151 ± 0.2426 | -0.138 ± 0.3356 |
| Glucose, Week 4 | 0.089 ± 0.2552 | 0.327 ± 1.2921 |
| Glucose, Week 8 | 0.030 ± 0.3929 | -0.026 ± 0.3219 |
| Glucose, Week 12 | 0.151 ± 0.2487 | -0.132 ± 0.3391 |
| Glucose, Week 24 | -0.169 ± 0.4133 | 0.468 ± 0.3080 |
| Glucose, Week 26 | -0.271 ± 0.3511 | 0.350 ± 0.6094 |
Blood samples was collected for the assessment of clinical chemistry parameters including direct bilirubin, bilirubin, and creatinine\[MB10.1\]. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Micromoles per Liter | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Direct Bilirubin, Week 1 | -0.62 ± 1.262 | 0.17 ± 0.996 |
| Direct Bilirubin, Week 4 | -0.30 ± 1.572 | -0.28 ± 1.778 |
| Direct Bilirubin, Week 8 | -0.77 ± 1.451 | 0.74 ± 1.059 |
| Direct Bilirubin, Week 12 | 0.12 ± 2.404 | 0.79 ± 0.862 |
| Direct Bilirubin, Week 24 | -0.12 ± 1.497 | 0.27 ± 1.228 |
| Direct Bilirubin, Week 26 | 0.22 ± 2.140 | 0.61 ± 2.781 |
| Bilirubin, Week 1 | -2.10 ± 3.544 | 0.14 ± 3.622 |
| Bilirubin, Week 4 | -1.19 ± 5.297 | -1.57 ± 6.771 |
| Bilirubin, Week 8 | -1.27 ± 4.252 | 0.99 ± 2.915 |
| Bilirubin, Week 12 | 1.03 ± 6.365 | 0.48 ± 2.618 |
| Bilirubin, Week 24 | -0.38 ± 4.361 | -0.32 ± 4.346 |
| Bilirubin, Week 26 | 1.06 ± 5.719 | -1.14 ± 8.219 |
| Creatinine, Week 1 | -0.6 ± 7.46 | -4.1 ± 4.09 |
| Creatinine, Week 4 | 0.7 ± 4.88 | 1.6 ± 6.19 |
| Creatinine, Week 8 | 2.5 ± 9.91 | 2.5 ± 6.72 |
| Creatinine, Week 12 | 0.1 ± 7.49 | -2.1 ± 5.71 |
| Creatinine, Week 24 | 0.1 ± 5.63 | -1.0 ± 7.19 |
| Creatinine, Week 26 | -1.5 ± 7.35 | -0.3 ± 6.75 |
Blood samples was collected for the assessment of clinical chemistry parameters including AST, ALT, ALP, and GGT. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Units Per Liter | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| ALP, Week 1 | -1.7 ± 4.92 | -1.9 ± 6.94 |
| ALP, Week 4 | 0.7 ± 7.17 | 1.3 ± 6.75 |
| ALP, Week 8 | 0.9 ± 7.23 | -2.7 ± 4.06 |
| ALP, Week 12 | 1.5 ± 6.88 | -3.4 ± 6.44 |
| ALP, Week 24 | 3.9 ± 9.34 | -0.9 ± 9.10 |
| ALP, Week 26 | 1.2 ± 6.99 | 1.6 ± 7.91 |
| ALT, Week 1 | 1.0 ± 6.70 | -3.4 ± 3.89 |
| ALT, Week 4 | -0.7 ± 4.32 | -2.8 ± 8.00 |
| ALT, Week 8 | 1.9 ± 6.67 | -0.8 ± 8.80 |
| ALT, Week 12 | 3.6 ± 6.70 | -1.9 ± 9.97 |
| ALT, Week 24 | 3.3 ± 9.24 | -3.1 ± 8.98 |
| ALT, Week 26 | 0.6 ± 6.59 | 0.9 ± 18.18 |
| AST, Week 1 | 1.5 ± 2.01 | -0.6 ± 5.13 |
| AST, Week 4 | 1.6 ± 3.72 | 0.6 ± 6.69 |
| AST, Week 8 | 1.3 ± 3.56 | -0.2 ± 2.86 |
| AST, Week 12 | 3.1 ± 4.04 | 2.1 ± 4.88 |
| AST, Week 24 | 2.9 ± 4.15 | 0.2 ± 2.91 |
| AST, Week 26 | 1.1 ± 3.48 | 4.8 ± 7.64 |
| GGT, Week 1 | 0.8 ± 2.94 | -0.5 ± 2.99 |
| GGT, Week 4 | 0.1 ± 2.23 | -0.2 ± 4.24 |
| GGT, Week 8 | 5.6 ± 5.97 | 4.1 ± 14.50 |
| GGT, Week 12 | 4.2 ± 3.19 | -0.4 ± 5.70 |
| GGT, Week 24 | 5.1 ± 7.82 | -0.1 ± 6.11 |
| GGT, Week 26 | 4.5 ± 4.70 | 0.1 ± 7.25 |
Blood samples was collected for the assessment of clinical chemistry parameters including Albumin. and Total Protein. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Grams per Liter | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Albumin, Week 1 | -1.13 ± 1.973 | -1.62 ± 1.266 |
| Albumin, Week 4 | -0.89 ± 2.529 | -0.83 ± 1.641 |
| Albumin, Week 8 | -0.03 ± 1.983 | -0.57 ± 2.434 |
| Albumin, Week 12 | -0.73 ± 1.800 | -0.56 ± 1.965 |
| Albumin, Week 24 | -2.12 ± 2.198 | 0.20 ± 1.356 |
| Albumin, Week 26 | -1.59 ± 2.366 | -0.24 ± 1.775 |
| Total Protein, Week 1 | -2.49 ± 3.504 | -2.02 ± 2.147 |
| Total Protein, Week 4 | -3.61 ± 4.100 | -1.60 ± 2.659 |
| Total Protein, Week 8 | -2.67 ± 3.492 | -1.80 ± 3.629 |
| Total Protein, Week 12 | -2.44 ± 2.274 | -2.02 ± 3.337 |
| Total Protein, Week 24 | -3.22 ± 3.858 | -1.71 ± 2.461 |
| Total Protein, Week 26 | -2.38 ± 3.379 | -2.86 ± 2.511 |
Blood samples were collected at indicated timepoints for analysis for complement (C3 and C4). Baseline was defined as latest pre-dose assessment with a non-missing value.
| Grams per Liter | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Complement C3, Baseline | 0.876 (0.780 to 0.985) | 0.913 (0.798 to 1.046) |
| Complement C3, Week 1 | 0.836 (0.745 to 0.939) | 0.899 (0.798 to 1.012) |
| Complement C3, Week 4 | 0.867 (0.788 to 0.954) | 0.840 (0.741 to 0.952) |
| Complement C3, Week 8 | 0.888 (0.796 to 0.990) | 0.896 (0.765 to 1.051) |
| Complement C3, Week 12 | 0.852 (0.755 to 0.961) | 0.888 (0.772 to 1.023) |
| Complement C3, Week 24 | 0.845 (0.754 to 0.948) | 0.912 (0.782 to 1.064) |
| Complement C3, Week 26 | 0.883 (0.781 to 0.998) | 0.886 (0.784 to 1.002) |
| Complement C4, Baseline | 0.211 (0.175 to 0.254) | 0.197 (0.175 to 0.223) |
| Complement C4, Week 1 | 0.205 (0.173 to 0.242) | 0.200 (0.175 to 0.228) |
| Complement C4, Week 4 | 0.202 (0.170 to 0.241) | 0.183 (0.156 to 0.214) |
| Complement C4, Week 8 | 0.201 (0.172 to 0.234) | 0.202 (0.174 to 0.235) |
| Complement C4, Week 12 | 0.194 (0.163 to 0.231) | 0.213 (0.172 to 0.263) |
| Complement C4, Week 24 | 0.205 (0.174 to 0.242) | 0.200 (0.168 to 0.238) |
| Complement C4, Week 26 | 0.219 (0.184 to 0.261) | 0.205 (0.178 to 0.235) |
Blood samples were collected at indicated timepoints for analysis for complement (C3 and C4). Baseline was defined as latest pre-dose assessment with a non-missing value.
| Ratio | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Complement C3, Week 1 Ratio to Baseline | 0.954 (0.889 to 1.024) | 0.984 (0.915 to 1.059) |
| Complement C3, Week 4, Ratio to Baseline | 0.989 (0.945 to 1.036) | 0.919 (0.830 to 1.019) |
| Complement C3, Week 8, Ratio to Baseline | 1.013 (0.935 to 1.098) | 0.981 (0.865 to 1.114) |
| Complement C3, Week 12, Ratio to Baseline | 0.972 (0.907 to 1.042) | 1.002 (0.913 to 1.100) |
| Complement C3, Week 24, Ratio to Baseline | 0.965 (0.876 to 1.062) | 1.028 (0.976 to 1.084) |
| Complement C3, Week 26, Ratio to Baseline | 1.008 (0.934 to 1.087) | 0.999 (0.920 to 1.085) |
| Complement C4, Week 1, Ratio to Baseline | 0.972 (0.863 to 1.095) | 1.013 (0.895 to 1.146) |
| Complement C4, Week 4, Ratio to Baseline | 0.959 (0.821 to 1.119) | 0.926 (0.813 to 1.056) |
| Complement C4, Week 8, Ratio to Baseline | 0.952 (0.850 to 1.067) | 1.024 (0.858 to 1.222) |
| Complement C4, Week 12, Ratio to Baseline | 0.919 (0.813 to 1.040) | 1.101 (0.972 to 1.246) |
| Complement C4, Week 24, Ratio to Baseline | 0.973 (0.873 to 1.085) | 1.034 (0.952 to 1.122) |
| Complement C4, Week 26, Ratio to Baseline | 1.040 (0.925 to 1.168) | 1.060 (0.989 to 1.135) |
Systolic blood pressure (sBP) is a measure of blood pressure while the heart is beating. Diastolic blood pressure (dBP) is a measure of blood pressure while the heart is relaxed. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Millimeters of mercury (mmHg) | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| sBP, Day 1 (2 hours) | -4.48 ± 6.933 | 0.34 ± 6.963 |
| sBP, Day 1 (8 hours) | 1.22 ± 6.522 | 2.54 ± 6.318 |
| sBP, Day 2 | 1.72 ± 6.086 | 1.34 ± 7.115 |
| sBP, Day 3 | 1.22 ± 7.632 | 2.64 ± 7.111 |
| sBP, Day 5 | 3.52 ± 8.877 | 2.24 ± 7.363 |
| sBP, Week 1 | 4.72 ± 7.952 | -1.36 ± 6.679 |
| sBP, Week 2 | 1.92 ± 5.797 | 0.74 ± 3.063 |
| sBP, Week 4 | 0.02 ± 6.091 | -0.06 ± 5.622 |
| sBP, Week 8 | 4.92 ± 5.034 | -0.66 ± 6.173 |
| sBP, Week 12 | -2.18 ± 7.916 | 0.08 ± 6.943 |
| sBP, Week 18 | -1.18 ± 10.532 | 0.52 ± 6.905 |
| sBP, Week 24 | -2.78 ± 5.849 | 4.52 ± 10.418 |
| sBP, Week 26 | -4.88 ± 8.527 | 2.97 ± 8.819 |
| dBP, Day 1 (2 hours) | 1.30 ± 7.002 | -1.99 ± 7.861 |
| dBP, Day 1 (8 hours) | 1.90 ± 5.045 | 0.11 ± 5.180 |
| dBP, Day 2 | 1.40 ± 3.960 | -2.29 ± 5.842 |
| dBP, Day 3 | 1.60 ± 2.823 | -3.09 ± 6.931 |
| dBP, Day 5 | 3.10 ± 6.056 | -1.89 ± 6.662 |
| dBP, Week 1 | 4.90 ± 4.303 | -3.39 ± 6.107 |
| dBP, Week 2 | 5.20 ± 4.454 | -4.59 ± 4.786 |
| dBP, Week 4 | 4.50 ± 4.463 | -2.59 ± 5.633 |
| dBP, Week 8 | 4.20 ± 6.244 | -2.49 ± 6.243 |
| dBP, Week 12 | 3.20 ± 5.759 | -1.96 ± 6.028 |
| dBP, Week 18 | 4.10 ± 4.078 | -1.07 ± 6.905 |
| dBP, Week 24 | 3.50 ± 4.622 | -1.73 ± 6.803 |
| dBP, Week 26 | 2.50 ± 4.602 | 0.93 ± 8.825 |
Body temperature was measured in participants in resting state. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Degrees Celsius | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Day 1, 2 hours | 0.07 ± 0.291 | 0.19 ± 0.328 |
| Day 1, 8 hours | 0.21 ± 0.152 | 0.44 ± 0.284 |
| Day 2 | -0.05 ± 0.259 | 0.12 ± 0.339 |
| Day 3 | -0.10 ± 0.353 | 0.11 ± 0.247 |
| Day 5 | -0.05 ± 0.341 | 0.45 ± 0.381 |
| Week 1 | -0.25 ± 0.360 | 0.16 ± 0.295 |
| Week 2 | 0.01 ± 0.303 | 0.20 ± 0.380 |
| Week 4 | -0.18 ± 0.336 | -0.09 ± 0.335 |
| Week 8 | -0.14 ± 0.212 | 0.28 ± 0.286 |
| Week 12 | -0.05 ± 0.331 | 0.29 ± 0.330 |
| Week 18 | -0.04 ± 0.347 | 0.11 ± 0.314 |
| Week 24 | 0.01 ± 0.285 | 0.11 ± 0.440 |
| Week 26 | 0.20 ± 0.316 | 0.37 ± 0.421 |
The vital signs followed in this analysis was pulse rate, expressed as beats per minute (bpm). Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Beats per minute (BPM) | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Pulse Rate, Day 1, 2 hour | -5.96 ± 5.529 | 2.13 ± 6.755 |
| Pulse Rate, Day 1, 8 hour | -4.16 ± 5.999 | 1.63 ± 5.892 |
| Pulse Rate, Day 2 | 7.24 ± 7.626 | 9.53 ± 8.596 |
| Pulse Rate, Day 3 | 1.14 ± 9.195 | 4.53 ± 9.833 |
| Pulse Rate, Day 5 | 4.74 ± 13.378 | 6.83 ± 8.631 |
| Pulse Rate, Week 1 | 0.94 ± 9.393 | 5.73 ± 6.001 |
| Pulse Rate, Week 2 | 5.24 ± 9.965 | 8.53 ± 5.714 |
| Pulse Rate, Week 4 | 2.24 ± 10.036 | 7.73 ± 10.994 |
| Pulse Rate, Week 8 | 1.24 ± 9.359 | 5.13 ± 8.495 |
| Pulse Rate, Week 12 | 0.54 ± 12.479 | 6.62 ± 11.918 |
| Pulse Rate, Week 18 | 3.04 ± 15.689 | 11.73 ± 12.640 |
| Pulse Rate, Week 24 | -0.06 ± 13.603 | 14.73 ± 9.943 |
| Pulse Rate, Week 26 | 3.74 ± 15.365 | 14.73 ± 11.377 |
12-lead ECG were performed in a supine position using an automated ECG machine that calculated the heart rate and measured PR interval, QRS duration, QT interval and corrected QT using Fridericia's Formula (QTc\[MB13.1\]F) intervals. ECG measurements were performed in triplicate. When multiple ECGs were performed at the same planned timepoint, the aggregate \[MB14.1\]value of each parameter was used. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Milliseconds | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| PR Interval, Aggregate, Day 1, 2 hour | -0.84 ± 4.344 | -2.64 ± 12.942 |
| PR Interval, Aggregate, Day 1, 8 hour | -2.27 ± 3.900 | -3.65 ± 11.480 |
| PR Interval, Aggregate, Day 2 | 4.53 ± 12.204 | -0.46 ± 13.476 |
| PR Interval, Aggregate, Day 3 | -0.20 ± 8.295 | 0.23 ± 9.007 |
| PR Interval, Aggregate, Day 5 | 1.33 ± 7.378 | -3.38 ± 12.322 |
| PR Interval, Aggregate, Week 1 | 1.08 ± 8.925 | -0.92 ± 11.653 |
| PR Interval, Aggregate, Week 2 | 4.04 ± 16.780 | 0.07 ± 9.145 |
| PR Interval, Aggregate, Week 4 | 5.45 ± 11.707 | 2.43 ± 12.669 |
| PR Interval, Aggregate, Week 8 | 3.46 ± 5.707 | 0.83 ± 11.991 |
| PR Interval, Aggregate, Week 12 | 2.53 ± 4.195 | -1.60 ± 15.803 |
| PR Interval, Aggregate, Week 18 | 1.78 ± 3.036 | -1.32 ± 11.759 |
| PR Interval, Aggregate, Week 24 | 2.13 ± 3.876 | -0.36 ± 15.513 |
| PR Interval, Aggregate, Week 26 | 4.40 ± 7.092 | -2.89 ± 11.269 |
| QRS Duration, Aggregate, Day 1, 2 hour | -1.63 ± 1.493 | -0.82 ± 2.483 |
| QRS Duration, Aggregate, Day 1, 8 hour | -0.48 ± 1.954 | -1.26 ± 1.973 |
| QRS Duration, Aggregate, Day 2 | 0.39 ± 2.023 | 0.00 ± 2.253 |
| QRS Duration, Aggregate, Day 3 | 1.89 ± 2.821 | 0.41 ± 1.902 |
| QRS Duration, Aggregate, Day 5 | -0.36 ± 2.627 | -0.34 ± 3.247 |
| QRS Duration, Aggregate, Week 1 | 0.03 ± 1.737 | -2.27 ± 2.295 |
| QRS Duration, Aggregate, Week 2 | 0.26 ± 2.196 | -0.93 ± 1.937 |
| QRS Duration, Aggregate, Week 4 | 0.15 ± 3.106 | -0.59 ± 1.954 |
| QRS Duration, Aggregate, Week 8 | 1.19 ± 2.745 | -0.80 ± 2.106 |
| QRS Duration, Aggregate, Week 12 | 0.93 ± 3.296 | -0.81 ± 2.597 |
| QRS Duration, Aggregate, Week 18 | 1.40 ± 3.351 | 0.02 ± 3.145 |
| QRS Duration, Aggregate, Week 24 | 0.46 ± 1.795 | -2.14 ± 2.546 |
| QRS Duration, Aggregate, Week 26 | -0.41 ± 3.316 | -4.07 ± 2.887 |
| QT Interval, Aggregate, Day 1, 2 hour | -5.21 ± 5.651 | -8.39 ± 17.499 |
| QT Interval, Aggregate, Day 1, 8 hour | -1.39 ± 8.188 | -6.92 ± 16.608 |
| QT Interval, Aggregate, Day 2 | -18.21 ± 8.801 | -21.93 ± 9.133 |
| QT Interval, Aggregate, Day 3 | -16.94 ± 14.136 | -34.99 ± 18.932 |
| QT Interval, Aggregate, Day 5 | -20.66 ± 16.160 | -19.39 ± 15.006 |
| QT Interval, Aggregate, Week 1 | -4.01 ± 12.293 | -8.60 ± 16.612 |
| QT Interval, Aggregate, Week 2 | -15.61 ± 17.242 | -17.66 ± 12.158 |
| QT Interval, Aggregate, Week 4 | -11.01 ± 14.937 | -11.07 ± 21.302 |
| QT Interval, Aggregate, Week 8 | -10.34 ± 14.871 | -11.67 ± 13.038 |
| QT Interval, Aggregate, Week 12 | -7.13 ± 18.140 | -12.78 ± 18.728 |
| QT Interval, Aggregate, Week 18 | -4.47 ± 22.321 | -19.39 ± 20.395 |
| QT Interval, Aggregate, Week 24 | -6.01 ± 26.007 | -23.96 ± 16.773 |
| QT Interval, Aggregate, Week 26 | -7.27 ± 22.688 | -33.78 ± 17.359 |
| QTcF Interval, Aggregate, Day 1, 2 hour | -12.59 ± 3.511 | -11.63 ± 16.082 |
| QTcF Interval, Aggregate, Day 1, 8 hour | -6.20 ± 6.892 | -7.97 ± 7.896 |
| QTcF Interval, Aggregate, Day 2 | -5.97 ± 6.321 | -9.73 ± 7.506 |
| QTcF Interval, Aggregate, Day 3 | -10.09 ± 6.675 | -26.49 ± 9.100 |
| QTcF Interval, Aggregate, Day 5 | -7.04 ± 8.360 | -9.57 ± 8.345 |
| QTcF Interval, Aggregate, Week 1 | -2.82 ± 6.837 | -3.45 ± 10.648 |
| QTcF Interval, Aggregate, Week 2 | -4.94 ± 6.690 | -7.17 ± 10.401 |
| QTcF Interval, Aggregate, Week 4 | -2.34 ± 5.754 | -5.07 ± 10.253 |
| QTcF Interval, Aggregate, Week 8 | -2.91 ± 7.425 | -4.00 ± 9.108 |
| QTcF Interval, Aggregate, Week 12 | -1.84 ± 4.347 | -5.67 ± 10.444 |
| QTcF Interval, Aggregate, Week 18 | 4.98 ± 5.990 | -2.93 ± 10.040 |
| QTcF Interval, Aggregate, Week 24 | 0.62 ± 8.127 | -8.71 ± 6.705 |
| QTcF Interval, Aggregate, Week 26 | -1.71 ± 6.968 | -11.20 ± 10.311 |
Serum samples were collected to determine the presence of anti-depemokimab binding antibodies using a validated bioanalytical method. Data is reported by visit. The results were categorized as negative and positive. A participant is considered positive if they have at least one positive post-Baseline ADA result. Number of participants with positive ADAs against depemokimab was reported in this outcome measure.
| Participants | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Day 1, Pre-dose | 0 | 0 |
| Week 4 | 0 | 0 |
| Week 12 | 0 | 0 |
| Week 26 | 0 | 0 |
Serum samples were collected to determine the presence of anti-depemokimab binding antibodies using a validated bioanalytical method. Data is reported by visit. Titer was only measured when a positive result was found.
No measurements were reported for this outcome.
Collected over All-cause mortality, Serious Adverse events (SAE) and non-SAEs were collected from the start of the study intervention (Day 1) up to Day 211 (End of follow-up).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Depemokimab 100mg | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Depemokimab 300mg | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Event | Depemokimab 100mg | Depemokimab 300mg |
|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 8/10 | 4/10 |
| Albumin urine presentInvestigations | 1/10 | 5/10 |
| Blood uric acid increasedInvestigations | 3/10 | 4/10 |
| Red blood cells urine positiveInvestigations | 1/10 | 3/10 |
| Protein urine presentInvestigations | 0/10 | 3/10 |
| Urinary casts presentInvestigations | 0/10 | 3/10 |
| Neutrophil count increasedInvestigations | 2/10 | 1/10 |
| Protein total decreasedInvestigations | 2/10 | 1/10 |
| Bilirubin conjugated increasedInvestigations | 0/10 | 2/10 |
| Upper respiratory tract infectionInfections and infestations | 2/10 | 1/10 |
| Age, Continuous(Years) | Depemokimab 100mg | Depemokimab 300mg | Total |
|---|---|---|---|
| Mean | 30.0 ± 6.23 | 29.4 ± 6.92 | 29.7 ± 6.41 |
| Sex: Female, Male(Participants) | Depemokimab 100mg | Depemokimab 300mg | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 10 | 10 | 20 |
| Race/Ethnicity, Customized(Participants) | Depemokimab 100mg | Depemokimab 300mg | Total |
|---|---|---|---|
| Asian - East Asian Heritage | 10 | 10 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://d3l8i7lo48obsd.cloudfront.net/gsk-patient-level-data-sharing-july2025-1-Bgwa1UthxvluYbWYTThw.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · d3l8i7lo48obsd.cloudfront.net
Ran from Dec 2021 to primary completion in Dec 2022, 12 months.
Results were first posted in May 2026, 3 years 5 months after primary completion.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 12 months is above that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Depemokimab